RTOG Protocol 81-08, a feasibility study of hyperfractionated radiation therapy (HFX) with 1.2 Gy twice daily separated by 4-6 hours for non-small-cell cancer of the lung (NSCCL), was completed in 1983. Encouraging short-term results in a recently closed trial of HFX for NSCCL (RTOG 83-11) led to assessment of long-term outcome in the earlier trial. Of 120 evaluable patients who were assigned to total doses from 50.4 Gy to 74.4 Gy, all 5 of the 5-year survivors came from the 79 patients assigned to receive 69.6 Gy. The 5-year survival rates for the 79 patients were 14.3 +/- 9.4% for clinical RTOG Stage II, 5.9 +/- 4.0% for Stage III, and 3.2 +/- 3.2% for Stage IV. Combined Stage II and III 5-year survival rates were 8.3 +/- 4.0% for HFX 69.6 Gy compared to 5.6 +/- 1.5% for standard once-a-day irradiation in concurrent RTOG trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000421-199108000-00002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA).
JCO Glob Oncol
January 2025
Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Purpose: Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world.
View Article and Find Full Text PDFMicrostrip plastic scintillating detector system for quality assurance in synchrotron microbeam radiotherapy.
Sci Rep
January 2025
Universite Claude Bernard Lyon 1, INL, UMR5270, CNRS, INSA Lyon, Ecole Centrale de Lyon, CPE Lyon, 69622, Villeurbanne, France.
Synchrotron microbeam radiotherapy (MRT), which has entered the clinical transfer phase, requires the development of appropriate quality assurance (QA) tools due to very high dose rates and spatial hyperfractionation. A microstrip plastic scintillating detector system with associated modules was proposed in the context of real-time MRT QA. A prototype of such a system with 105 scintillating microstrips was developed and tested under MRT conditions.
View Article and Find Full Text PDFHyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma.
Front Immunol
December 2024
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Background: Bridging therapy can prevent patients from disease progression while waiting for CAR-T cell preparation. Hyper-fractionated radiotherapy can achieve an effective target dose within a short period, minimize radiation damage, and may modify immune environment compared to conventional radiotherapy.
Aims: This study aims to investigate the efficacy and safety of bridging hyper-fractionated radiotherapy in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma.
Surgical management of skull base and spinal chordomas: A case series with comprehensive review of the literature.
N Am Spine Soc J
December 2024
Department of Neurosurgery, University of Iowa Carver, College of Medicine, Iowa City, IA, United States.
Background: Chordomas are rare, slow growing, locally aggressive malignant bone tumors that arise from remnants of the embryonic notochord with variable presenting symptoms depending on tumor location.
Methods: All patients with craniospinal chordoma managed at our institution between 1982 and 2023 were retrospectively reviewed. Demographics, tumor characteristics, clinical course and treatment, and long-term neurological and survival outcomes were collected.
Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study.
Strahlenther Onkol
October 2024
Department of Radiation Oncology, Münster University Hospital, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Purpose: This study aimed to analyze treatment-related risk factors for sensorineural hearing loss (SNHL) and an indication for hearing aids (IHA) in medulloblastoma patients after craniospinal radiotherapy (CSRT) and platin-based chemotherapy (PCth).
Methods: A total of 58 patients (116 ears) with medulloblastoma and clinically non-relevant pre-treatment hearing thresholds were included. Cranial radiotherapy and PCth were applied sequentially according to the HIT 2000 study protocol or post-study recommendations, the NOA-07 protocol, or the PNET (primitive neuroectodermal tumor) 5 MB therapy protocol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!